Industry Strength Score
66/100
Composite price performance score based on 3, 6, and 12-month returns, with more weight on recent trends.
ADAMIS PHARMACEUTICALS CORP (ADMP) Stock Price & Overview
NASDAQ:ADMP • US00547W3079
Current stock price
0.7751 USD
+0.01 (+0.86%)
At close:
0.77 USD
-0.01 (-0.66%)
After Hours:
The current stock price of ADMP is 0.7751 USD. Today ADMP is up by 0.86%. In the past month the price decreased by -42.59%. In the past year, price decreased by -96.65%.
ADMP Key Statistics
52-Week Range0.75 - 26.18
Current ADMP stock price positioned within its 52-week range.
1-Month Range0.75 - 1.33
Current ADMP stock price positioned within its 1-month range.
- Market Cap
- 2.163M
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -11.03
- Dividend Yield
- N/A
ADMP Stock Performance
Today
+0.86%
1 Week
-4.57%
1 Month
-42.59%
3 Months
-62.19%
Longer-term
6 Months -91.55%
1 Year -96.65%
2 Years N/A
3 Years N/A
5 Years N/A
10 Years N/A
ADMP Stock Chart
ADMP Technical Analysis
ChartMill assigns a technical rating of 0 / 10 to ADMP. When comparing the yearly performance of all stocks, ADMP is a bad performer in the overall market: 98.96% of all stocks are doing better.
Chartmill TA Rating
Chartmill Setup Rating
ADMP Earnings
Next Earnings DateNov 13, 2023
Last Earnings DateAug 8, 2023
PeriodQ2 / 2023
EPS Reported
Revenue Reported
EPS Surprise %
Revenue Surprise %
ADMP Forecast & Estimates
6 analysts have analysed ADMP and the average price target is 0.43 USD. This implies a price decrease of -44.73% is expected in the next year compared to the current price of 0.7751.
Analysts
Analysts43.33
Price Target0.43 (-44.52%)
EPS Next YN/A
Revenue Next YearN/A
ADMP Financial Highlights
Over the last trailing twelve months ADMP reported a non-GAAP Earnings per Share(EPS) of -11.03. The EPS increased by 40.47% compared to the year before.
Income Statements
Revenue(TTM)5.12M
Net Income(TTM)-25.24M
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | N/A | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
Chartmill High Growth Momentum
EPS Q2Q%14.18%
Sales Q2Q%120%
EPS 1Y (TTM)40.47%
Revenue 1Y (TTM)700%
ADMP Ownership
Ownership
Inst Owners0%
Shares2.79M
Float9.28M
Ins Owners95.51%
Short Float %N/A
Short RatioN/A
ADMP Industry Overview
ADMP operates in the Pharmaceuticals sub-industry within the Health Care sector. This group contains 135 stocks and is scored by ChartMill on both price strength and growth momentum.
Industry Growth Score
16/100
Composite growth score based on earnings growth, revenue growth, and profitability across the sub-industry.
Relative Performance
Each rank shows how many other sub-industries were outperformed over that timeframe.
1 Month Rank
34%
Outperformed 34% of sub-industries
3 Month Rank
52%
Outperformed 52% of sub-industries
6 Month Rank
39%
Outperformed 39% of sub-industries
Industry Fundamentals & Breadth
- Members
- 135
- New Highs
- 4.4%
- New Lows
- 3.7%
- Average ROE
- 50.3%
- Average Profit Margin
- 27.8%
- Average Operating Margin
- 37.4%
- Average P/E
- 26.4
- Average Fwd P/E
- 20.7
- Average Debt/Equity
- 1.2
ADMP Competitors/Peers
The largest stocks on the US markets in the "Pharmaceuticals" sub-industry
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 21.96 | 883.029B | ||
| JNJ | JOHNSON & JOHNSON | 18.12 | 553.619B | ||
| MRK | MERCK & CO. INC. | 11.13 | 269.662B | ||
| PFE | PFIZER INC | 8.93 | 151.879B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 9.79 | 123.709B | ||
| ZTS | ZOETIS INC | 16.26 | 48.347B | ||
| RPRX | ROYALTY PHARMA PLC- CL A | 9.69 | 28.899B | ||
| VTRS | VIATRIS INC | 5.99 | 17.396B | ||
| ELAN | ELANCO ANIMAL HEALTH INC | 21.26 | 11.171B | ||
| AXSM | AXSOME THERAPEUTICS INC | N/A | 10.626B | ||
| TERN | TERNS PHARMACEUTICALS INC | N/A | 6.109B | ||
| BLTE | BELITE BIO INC - ADR | N/A | 5.971B | ||
| CORT | CORCEPT THERAPEUTICS INC | 32.16 | 4.948B |
Related stock screener links
View all stocks in the Pharmaceuticals Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About ADMP
Company Profile
Adamis Pharmaceuticals Corp. is a biopharmaceutical company, which engages in the discovery, development, and sale of pharmaceutical, specialty biopharmaceutical, and other drug products. The company is headquartered in San Diego, California and currently employs 11 full-time employees. Its products in the allergy, respiratory and opioid overdose markets include SYMJEPI (epinephrine) Injection 0.3mg, SYMJEPI (epinephrine) Injection 0.15mg and ZIMHI (naloxone HCL Injection, USP) 5 mg/0.5 mL. SYMJEPI (epinephrine) Injection 0.3mg is approved by the United States Food and Drug Administration (FDA) for use in the emergency treatment of acute allergic reactions, including anaphylaxis, for patients weighing 66 pounds or more. SYMJEPI (epinephrine) Injection 0.15mg is approved by the FDA for use in the treatment of anaphylaxis for patients weighing 33-65 pounds. ZIMHI (naloxone HCL Injection, USP) 5 mg/0.5 mL is approved by the FDA for the treatment of opioid overdose. The firm's Tempol, is an investigational drug.
Company Info
IPO: 1995-08-14
ADAMIS PHARMACEUTICALS CORP
Suite 310, 11455 El Camino Real
San Diego CALIFORNIA 92130 US
CEO: Dennis J. Carlo
Employees: 11
Phone: 18589972400.0
ADAMIS PHARMACEUTICALS CORP / ADMP FAQ
What does ADAMIS PHARMACEUTICALS CORP do?
Adamis Pharmaceuticals Corp. is a biopharmaceutical company, which engages in the discovery, development, and sale of pharmaceutical, specialty biopharmaceutical, and other drug products. The company is headquartered in San Diego, California and currently employs 11 full-time employees. Its products in the allergy, respiratory and opioid overdose markets include SYMJEPI (epinephrine) Injection 0.3mg, SYMJEPI (epinephrine) Injection 0.15mg and ZIMHI (naloxone HCL Injection, USP) 5 mg/0.5 mL. SYMJEPI (epinephrine) Injection 0.3mg is approved by the United States Food and Drug Administration (FDA) for use in the emergency treatment of acute allergic reactions, including anaphylaxis, for patients weighing 66 pounds or more. SYMJEPI (epinephrine) Injection 0.15mg is approved by the FDA for use in the treatment of anaphylaxis for patients weighing 33-65 pounds. ZIMHI (naloxone HCL Injection, USP) 5 mg/0.5 mL is approved by the FDA for the treatment of opioid overdose. The firm's Tempol, is an investigational drug.
Can you provide the latest stock price for ADAMIS PHARMACEUTICALS CORP?
The current stock price of ADMP is 0.7751 USD. The price increased by 0.86% in the last trading session.
Does ADAMIS PHARMACEUTICALS CORP pay dividends?
ADMP does not pay a dividend.
How is the ChartMill rating for ADAMIS PHARMACEUTICALS CORP?
ADMP has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 0 out of 10.
What is the GICS sector and industry of ADMP stock?
ADAMIS PHARMACEUTICALS CORP (ADMP) operates in the Health Care sector and the Pharmaceuticals industry.
Can you provide the upcoming earnings date for ADAMIS PHARMACEUTICALS CORP?
ADAMIS PHARMACEUTICALS CORP (ADMP) will report earnings on 2023-11-13, after the market close.